Xeltis AG
Spontaneous natural tissue growth for heart valve replacement
This article was originally published in Start Up
Executive Summary
Rather than relying on an animal or cadaver implant to repair severe congenital heart malformations, Xeltis AG has developed a synthetic and biodegradable replacement pulmonary valve, designed to stimulate and guide the body’s natural healing response. The company’s technology, which has opened up an entirely new therapeutic category called endogenous tissue growth, is designed to provide a single intervention that can last for a lifetime.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.